Lilly to shell out billions of dollars to acquire Loxo Oncology
US pharma major Eli Lilly (NYSE: LLY) today announced the second multi-billion dollar acquisition of the New Year, saying it had reached a definitive agreement to acquire Loxo Oncology (Nasdaq: LOXO), with the news sending the latter’s shares up about 63.8% at $229 in pre-market trading today. Lilly was down 2.67% at $111.60 pre-market.
Lilly is offering $235.00 per share in cash, which represents a premium of about 68% to Loxo’s Friday close, or around $8.0 billion. Loxo Oncology is a biopharmaceutical company focused on the development and commercialization of highly selective medicines for patients with genomically defined cancers.
Just last week, Bristol-Myers Squibb (NYSE: BMY) kicked off the MA& season with a $74 billion bid for Celgene (Nasdaq: CELG).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze